Chemokine starts phase 1b/2 human clinical trial in cancer

By Elaine Rigoli

Tampa, Fla., May 2 - Chemokine Therapeutics Corp. has started patient dosing in a phase 1b/2 clinical trial using CTCE-9908, the company's lead anticancer product.

The start of this trial is an important milestone for the company as it will be the first investigation of CTCE-9908's safety and ability to reduce the spread of cancer in humans after several doses, according to a news release.

A previously completed phase 1 clinical trial demonstrated CTCE-9908 to be safe and well tolerated by study subjects after a single dose, the release said.

The new trial will involve testing the drug in up to 30 patients with late-stage cancers to evaluate safety and preliminary efficacy.

The trial will study CTCE-9908 in patients with some of the most common cancers such as breast, lung, prostate and ovarian.

"This trial is our first opportunity to show safety and early efficacy of CTCE-9908 in a repeat dose setting, an important clinical step that has real potential to add value to our programs and shareholders," president and chief executive officer Hassan Salari said in the release.

Chemokine Therapeutics is a Vancouver, B.C.-based biotechnology company developing drugs that harness the therapeutic potential of stem cells through chemokine pathways.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.